RSV Seasonal Vaccine Introduction and Growth Strategy
Q2 2023 sales £7.1bn¹, +11%¹
Strong commercial execution across all product areas and key medicines
Vaccines +15%¹
.
Shingrix+20%: another record
quarter with continued growth ex-US;
now launched in 33 markets, most with
<3% penetration ex-US
.
Bexsero +18%
Specialty Medicines +12%1
.
Benlysta+19%
•
Nucala +15% and market leader in IL5
share
.
Oncology -3%
General Medicines +8%
Trelegy+30%: best-in-class access with
leading US share of voice.
⚫ #1 prescribed SITT2 worldwide in
>60 countries
Shingrix sales by geography
100%
30% 29%
80%
38% 38%
39%
46%
60%
40%
70% 71%
63%
62%
61%
54%
20%
0%
Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023
US
EU+International
HIV +12%
Nucala EOS-driven indications
driving growth and differentiation
•
Severe Eosinophilic Asthma
Hyper Eosinophilic Syndrome
Chronic Rhinosinusitis
with Nasal Polyps
Eosinophilic Granulomatosis
with Polyangiitis
Phase III COPD data: H2 2024
Trelegy global sales
Sales (£m)
650
550
450
350
250
150
50
2021
2022
2023
Q1 Q2 Q3 Q4
GSK
Absolute values at AER; changes at CER, unless stated otherwise
1. Excluding COVID-19 solutions 2. Single inhaler triple therapy
16
10View entire presentation